

Monique B Nilsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2862328/publications.pdf>

Version: 2024-02-01

29
papers

3,120
citations

361413

20
h-index

477307

29
g-index

30
all docs

30
docs citations

30
times ranked

5463
citing authors

#	ARTICLE	IF	CITATIONS
1	An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 279-290.	7.0	848
2	Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. <i>Nature Medicine</i> , 2018, 24, 638-646.	30.7	351
3	Interleukin-6, Secreted by Human Ovarian Carcinoma Cells, Is a Potent Proangiogenic Cytokine. <i>Cancer Research</i> , 2005, 65, 10794-10800.	0.9	299
4	Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2018, 24, 6195-6203.	7.0	292
5	Structure-based classification predicts drug response in EGFR-mutant NSCLC. <i>Nature</i> , 2021, 597, 732-737.	27.8	185
6	Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 205-215.	1.1	149
7	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. <i>Cancer Cell</i> , 2019, 36, 444-457.e7.	16.8	145
8	Stress Hormones Regulate Interleukin-6 Expression by Human Ovarian Carcinoma Cells through a Src-dependent Mechanism. <i>Journal of Biological Chemistry</i> , 2007, 282, 29919-29926.	3.4	134
9	A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	101
10	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β -blockers. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	96
11	Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0152584.	2.5	65
12	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021, 16, 583-600.	1.1	62
13	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1611-1623.	1.1	43
14	Tumor Endothelial Markers Define Novel Subsets of Cancer-Specific Circulating Endothelial Cells Associated with Antitumor Efficacy. <i>Cancer Research</i> , 2014, 74, 2731-2741.	0.9	41
15	β -Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 27-36.	4.1	35
16	Altered Regulation of HIF-1 α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. <i>Journal of Thoracic Oncology</i> , 2021, 16, 439-451.	1.1	34
17	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1821-1839.	1.1	34
18	Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. <i>Cancer Cell</i> , 2022, 40, 754-767.e6.	16.8	34

#	ARTICLE	IF	CITATIONS
19	Vascular endothelial growth factor (VEGF) pathway. <i>Journal of Thoracic Oncology</i> , 2006, 1, 768-70.	1.1	22
20	Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with <i>T790M</i> mutations. <i>Oncotarget</i> , 2016, 7, 47998-48010.	1.8	21
21	Inhibition of nonsense-mediated decay rescues p53 ^{Δ13} isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. <i>Journal of Biological Chemistry</i> , 2021, 297, 101163.	3.4	18
22	Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , 2021, 14, 313-324.	1.5	17
23	KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. <i>Clinical Cancer Research</i> , 2016, 22, 1940-1950.	7.0	15
24	Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 246-257.	1.1	14
25	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 149, 33-40.	2.0	12
26	Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 14268-14284.	1.8	12
27	Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2051-2064.	1.1	6
28	ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC. <i>Cancer Cell</i> , 2021, 39, 1178-1180.	16.8	6
29	Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. <i>Molecular Cancer Research</i> , 2022, 20, 280-292.	3.4	4